Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Universities Must Keep Their Wits About Them When It Comes to Impact

22 October 2013

By Stephen Caddick, Vice-Provost (Enterprise) at UCL
Sir Andrew Witty's independent review of how universities can support growth has been published, to general approval.

As you'd expect from one of the world's top business leaders who has taken GlaxoSmithKline into the apex of global pharmaceutical giants, Witty's review is thoughtful and packed with evidence and data. It is also reasonably focused with a relatively small number of thoughtful recommendations.

Read the full article at www.huffingtonpost.co.uk